Irinotecan oral - Hanmi Pharmaceutical

Drug Profile

Irinotecan oral - Hanmi Pharmaceutical

Alternative Names: Irinotecan + HM 30181A; Irinotecan + HM30181AK; Irinotecan + HM30181AK-US; Oral irinotecan - Hanmi Pharmaceutical; Oratecan

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules; Vinca alkaloids
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 12 Sep 2018 Athenex and Hanmi Pharmaceutical revise the collaboration agreement to grant Athenex the rights to develop and commercialise Orascovery™-based products in the Middle East, North Africa and South Africa
  • 22 May 2018 Irinotecan is still in phase I trials for Solid tumours and Colorectal cancer (Hanmi pipeline, May 2018)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Colorectal-cancer in South Korea (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top